WOONSOCKET, R.I., May 2 /PRNewswire-FirstCall/ -- MultiCell
Technologies, Inc. (OTC Bulletin Board: MCET) has moved into new space and
will have a different address and telephone numbers. Effective May 1, 2008:
-- the new address is: 68 Cumberland Street, Suite 301, Woonsocket,
-- new phone number is: (401) 762-0045
-- the new fax number is: (401) 762-0098
MultiCell Technologies, Inc. is a biopharmaceutical company developing
new therapeutics including:
MCT-125 for the treatment of primary fatigue in MS patients.
MCT-175 for the treatment of relapsing-remitting MS.
MCT-465 for the treatment of TLR3 positive breast cancers.
MCT-475 for the treatment of TLR3 positive cervical cancers.
MultiCell also sells and/or licenses immortalized human liver cells to the pharmaceutical industry and holds patents on the Sybiol(R) synthetic bio-liver device and liver-derived adult human stem cells.
For more information about MultiCell Technologies, please visit http://www.multicelltech.com .
Caution Regarding Forward-Looking Statements
Any statements in this press release about MultiCell's expectations,
beliefs, plans, objectives, assumptions or future events or performance are
not historical facts and are forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). These
statements are often, but not always, made through the use of words or
phrases such as "believe," "will," "expect," "anticipate," "estimate,"
"intend," "plan," "forecast," "could," and "would." Examples of such
forward looking statements include statements regarding the timing, design,
scope, and anticipated results of our clinical development programs.
MultiCell bases these forward- looking statements on current expectations
about future events. They involve known and unknown risks, uncertain
|SOURCE MultiCell Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved